1. Home
  2. AREN vs OMER Comparison

AREN vs OMER Comparison

Compare AREN & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AREN
  • OMER
  • Stock Information
  • Founded
  • AREN 2016
  • OMER 1994
  • Country
  • AREN United States
  • OMER United States
  • Employees
  • AREN N/A
  • OMER N/A
  • Industry
  • AREN Medical/Dental Instruments
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • AREN Health Care
  • OMER Health Care
  • Exchange
  • AREN Nasdaq
  • OMER Nasdaq
  • Market Cap
  • AREN 305.8M
  • OMER 304.9M
  • IPO Year
  • AREN N/A
  • OMER 2009
  • Fundamental
  • Price
  • AREN $5.97
  • OMER $4.09
  • Analyst Decision
  • AREN Strong Buy
  • OMER Strong Buy
  • Analyst Count
  • AREN 1
  • OMER 5
  • Target Price
  • AREN $12.00
  • OMER $18.00
  • AVG Volume (30 Days)
  • AREN 239.1K
  • OMER 815.5K
  • Earning Date
  • AREN 11-13-2025
  • OMER 11-12-2025
  • Dividend Yield
  • AREN N/A
  • OMER N/A
  • EPS Growth
  • AREN N/A
  • OMER N/A
  • EPS
  • AREN 2.74
  • OMER N/A
  • Revenue
  • AREN $146,610,000.00
  • OMER N/A
  • Revenue This Year
  • AREN $29.48
  • OMER N/A
  • Revenue Next Year
  • AREN $11.72
  • OMER $9,040.39
  • P/E Ratio
  • AREN $2.16
  • OMER N/A
  • Revenue Growth
  • AREN 6.81
  • OMER N/A
  • 52 Week Low
  • AREN $0.56
  • OMER $2.95
  • 52 Week High
  • AREN $10.05
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • AREN 45.72
  • OMER 47.44
  • Support Level
  • AREN $5.17
  • OMER $4.07
  • Resistance Level
  • AREN $6.26
  • OMER $4.34
  • Average True Range (ATR)
  • AREN 0.42
  • OMER 0.17
  • MACD
  • AREN -0.05
  • OMER -0.04
  • Stochastic Oscillator
  • AREN 56.01
  • OMER 7.50

About AREN The Arena Group Holdings Inc.

The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: